| Literature DB >> 33193098 |
Sofia Marini1, Giuseppe Barone1, Alice Masini2, Laura Dallolio2, Laura Bragonzoni1, Yari Longobucco3, Francesca Maffei1.
Abstract
Background: Bone imbalance between anabolic and catabolic processes at the level of remodeling unit due to the prevalence of resorbing activity, represents a health problem of aging. The consequence is the negative balance of bone turnover that can lead to osteoporosis. Physical activity (PA) can play a central role in the comprehensive management of osteoporosis, since it induces the anabolism of bone tissue. Bone turnover biomarkers, reflecting the cellular activity linked to bone metabolism, can represent an evaluation tool to assess the efficacy of PA in the osteoporotic population. The aim of this systematic review, conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, was to investigate the effects of PA interventions on bone biomarkers in people with osteoporosis.Entities:
Keywords: bone biomarkers; bone metabolism; bone turnover; exercise; osteoporosis; physical activity; training
Year: 2020 PMID: 33193098 PMCID: PMC7644859 DOI: 10.3389/fendo.2020.585689
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555
Summary of bone turnover biomarkers currently available and their characteristics.
| Biomarkers | Assay method | Characteristics | Reference |
|---|---|---|---|
| Alkaline phosphatase (ALP) | Serum Standard Auto-analyzer technique | Widely used but non-specific for bone turnover | Vasikaran et al. ( |
| Bone alkaline phosphatase (BALP) | Serum EIA-CLEIA | Applied for the monitoring of osteoporosis. | Kuo and Chen ( |
| Osteocalcin (OC) | Serum IRMA-ECLIA | No significant utility for the assessment of osteoporosis. Promising for the investigation of osteoporosis therapy efficacy | Liu et al. ( |
| Procollagen type 1 C-terminal propeptide (P1CP) | Serum Radioimmunoassay | Limited study in literature. | Kuo and Chen ( |
| Procollagen type 1 N-terminal propeptide (P1NP) | Serum RIA-ECLIA | The most sensitive marker to measure the bone formation rate | Kuo and Chen ( |
| Amino-terminal crosslinked telopeptide of type 1 collagen (NTX-1) | Urine EIA-CLEIA | Stable and not affected by food intake. Promising marker for osteoporosis management | Kuo and Chen ( |
| Bone sialoprotein (BSP) | Serum immunoassay | Potential biomarker for osteoporosis assessment | Kuo and Chen ( |
| Carboxy-terminal crosslinked telopeptide of type 1 collagen (CTX-1) | Serum/plasma/urine EIA-CLEIA | Specific and sensitive biomarker for osteoporosis management. Useful marker for monitoring drug therapy | Kuo and Chen ( |
| Cathepsin K (CTSK) | Serum ELISA | Potential marker for monitoring drug therapy | Kuo and Chen ( |
| Deoxypyridinoline (DPD) | Urine HPLC-EIA-CLEIA | Not very sensitive for osteoporosis management | Kuo and Chen ( |
| Hydroxylysine (HYL) | Urine HPLC | Limited application due to the lack of a simple routine method | Kuo and Chen ( |
| Hydroxyproline (HYP) | Urine Spectrophotometric technique | Not very sensitive for osteoporosis management, it has been replaced by more specific markers | Kuo and Chen ( |
| Osteopontin (OP) | Plasma ELISA | Promising biomarker to monitor the parathyroid hormone treatment in menopausal osteoporosis | Kuo and Chen ( |
| Pyridinoline (PYD) | Urine HPLC | Non-specific for diagnosis and treatment of osteoporosis | Kuo and Chen ( |
| Tartrate-resistant acid phosphatase 5b | Serum/plasma EIA | Good specificity and high sensitivity for monitoring drug therapy | Kuo and Chen ( |
| Dickkopf-1 (DDK-1) | Serum ELISA | Insufficient clinical data for osteoporosis management | Kuo and Chen ( |
| Osteoprotegerin (OPG), | Serum ELISA | Insufficient data for clinical management of osteoporosis | Kuo and Chen ( |
| Receptor activator of NF-kB ligand (RANKL) | Serum ELISA | Insufficient data for diagnosis and treatment of osteoporosis | Kuo and Chen ( |
| Sclerostin | Serum ELISA | Insufficient clinical data for osteoporosis assessment | Kuo and Chen ( |
Figure 1PRISMA diagram of the study selection.
Studies included in the review.
| Study | Study design | Sample | Intervention | Outcomes | Results | Quality (RoB Tool) |
|---|---|---|---|---|---|---|
| Arazi et al. ( | RCT | N:40 age:30–45 | ||||
| El-Mekawy et al. ( | RCT | N: 60 womenage:59.03 ± 2.67 | ||||
| Roghani et al. ( | RCT | N:27 |